Heart Failure Reviews

, Volume 16, Issue 6, pp 609–614

The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome

Article

Abstract

Anemia is common in Congestive Heart Failure (CHF) and is associated with an increased mortality, morbidity and progressive renal failure. The most common causes of the anemia in CHF are (1) the associated Chronic Kidney Disease (CKD), which causes depression of erythropoietin (EPO) production in the kidney, and (2) excessive cytokine production in CHF, which can cause both depression of erythropoietin production in the kidney and depression of erythropoietin response in the bone marrow. The cytokines can also induce iron deficiency by increasing hepcidin production from the liver, which both reduces gastrointestinal iron absorption and reduces iron release from iron stores located in the macrophages and hepatocytes. It appears that iron deficiency is very common in CHF and is rarely recognized or treated. The iron deficiency can cause a thrombocytosis that might contribute to cardiovascular complications in both CHF and CKD and is reversible with iron treatment. Thus, attempts to control this anemia in CHF will have to take into consideration both the use of both Erythropoiesis Stimulating Agents (ESA) such as EPO and oral and, probably more importantly, intravenous (IV) iron. Many studies of anemia in CHF with ESA and oral or IV iron and even with IV iron without ESA have shown a positive effect on hospitalization, New York Heart Association functional class, cardiac and renal function, quality of life, exercise capacity and reduced Beta Natriuretic Peptide and have not demonstrated an increase in cardiovascular damage related to the therapy. However, adequately powered long-term placebo-controlled studies of ESA and of IV iron in CHF are still needed and are currently being carried out.

Keywords

Anemia Heart failure Renal failure Erythropoietin Iron Cardio renal syndrome 

References

  1. 1.
    Silverberg DS, Wexler D, Iaina A et al (2008) The role of anaemia in patients with congestive heart failure: a short review. Eur J Ht Failure 10:819–823CrossRefGoogle Scholar
  2. 2.
    Ghali JK (2009) Anemia and heart failure. Curr Opin Cardiol 24:172–178PubMedCrossRefGoogle Scholar
  3. 3.
    Silverberg DS, Wexler D, Palazzuoli A et al (2009) The anemia of heart failure. Acta Haematol 122:109–119PubMedCrossRefGoogle Scholar
  4. 4.
    Anand ISAnemia (2008) Chronic heart failure. J Am Coll Cardiol 52:501–511PubMedCrossRefGoogle Scholar
  5. 5.
    Groenwald HF, Januzzi JL, Damman K et al (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52:818–827CrossRefGoogle Scholar
  6. 6.
    He S-W, Wang L-X (2009) The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review. CHF 15:123–130PubMedGoogle Scholar
  7. 7.
    Tang WH, Tong W, Jain A et al (2008) Evaluation and long term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic renal failure. J Am Coll Cardiol 51:569–576PubMedCrossRefGoogle Scholar
  8. 8.
    Boerrigter G, Costello-Boerrigter LC, Abraham WT et al (2008) Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular function. J Cardiac Failure 14:539–546CrossRefGoogle Scholar
  9. 9.
    Opasich C, Cazzola M, Scelsi L et al (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Ht J 26:2232–2237CrossRefGoogle Scholar
  10. 10.
    Weiss G (2009) Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 1790:682–693PubMedGoogle Scholar
  11. 11.
    Nemeth E (2008) Iron regulation and erythropoiesis. Curr Opin Hematol 15:169–175PubMedCrossRefGoogle Scholar
  12. 12.
    Jankowska EA, Rozentryt P, Witkowska A et al (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31:1872–1880PubMedCrossRefGoogle Scholar
  13. 13.
    Nanas JN, Matsouka C, Karageorgopoulos D et al (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48:2485–2489PubMedCrossRefGoogle Scholar
  14. 14.
    Maeder MT, Khammy O, Dos Remedios C et al (2010) Myocardial and systemic iron depletion in heart failure. European Ht J 31(Abstract Supplement):567Google Scholar
  15. 15.
    Besarab A, Horl WA, Silverberg D (2009) Iron metabolism, iron deficiency, thrombocytosis and the cardiorenal anemia syndrome. Oncologist 14(Suppl 1):22–33PubMedCrossRefGoogle Scholar
  16. 16.
    Abramov D, Cohen RS, Katz SD et al (2008) Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fraction. Am J Cardiol 102:1069–1072PubMedCrossRefGoogle Scholar
  17. 17.
    Hyatt TC, Phadke RP, Hunter GR et al (2009) Insulin sensitivity in African Americans and white women. Obesity 17:276–282PubMedGoogle Scholar
  18. 18.
    Van der Meer P, Groenveld H, Januzzi JL et al (2009) Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 95:1309–1314PubMedCrossRefGoogle Scholar
  19. 19.
    Tehrani F, Dhesi P, Daneshvar D et al (2009) Erythropoiesis stimulating agents in heart failure patients with anemia: a metaanalysis. Cardiovascular Drugs Ther 23:511–518CrossRefGoogle Scholar
  20. 20.
    Ngo K, Kotecha D, Walters JA et al. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010 Jan 20:CD007613Google Scholar
  21. 21.
    Ghali J, Anand I, Abraham WT et al (2008) Randomized double blind trial of darbepoetin alpha treatment in patients with symptomatic heart failure and anemia. Circulation 117:526–535PubMedCrossRefGoogle Scholar
  22. 22.
    Klapholz M, Abraham WT, Ghali JK et al (2009) The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. Eur J Heart Failure 11:1071–1077CrossRefGoogle Scholar
  23. 23.
    Desai A, Lewis E, Solomon S, McMurray JJV, Pfeffer M (2010) Impact of erythropoiesis-stimulating agents on morbidity and mortality with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Failure 12:936–942CrossRefGoogle Scholar
  24. 24.
    Phommintikul A, Haas HJ, Elsik M et al (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369:381–388CrossRefGoogle Scholar
  25. 25.
    Rizzo JD, Somerfield MR, Hagerty KL et al (2008) Use of epoetin and darbepoetin in patients with cancer. American society of hematology/American society of clinical oncology clinical practice guideline update. Blood 111:25–41PubMedCrossRefGoogle Scholar
  26. 26.
    Pfeffer MA, Burdmann EA, Chen C-Y et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New Engl J Med 361:1–5CrossRefGoogle Scholar
  27. 27.
    Palmer SC, Navaneethan SD, Craig JC et al (2010) Meta-analysis: erythropoesis-stimulating agents in patients with chronic kidney disease. Ann Int Med 153:23–33PubMedGoogle Scholar
  28. 28.
    Szczech LA, Barnhart HX, Sapp S et al (2010) A secondary analysis of the CHOIR study shows that comorbid conditions affect outcomes during anemia treatment. Kidney Int 77:239–246PubMedCrossRefGoogle Scholar
  29. 29.
    McMurray JJ, Anand IS, Diaz R et al (2009) Design of the reduction of events with darbepoetin alfa in heart failure (RED-HF) a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11:795–801PubMedCrossRefGoogle Scholar
  30. 30.
    Singh AK (2010) ESA in dialysis patients:are you a hedgehog or a fox? J Am Soc Nephrol 21:543–545PubMedCrossRefGoogle Scholar
  31. 31.
    Berns JS. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy for anemia management in dialysis patients. Curr Opin Nephrol and Hypertens 2010 (epub)Google Scholar
  32. 32.
    Maiese K, Li F, Chong ZZ (2005) New avenues of exploration for erythropoietin. JAMA 293:90–95PubMedCrossRefGoogle Scholar
  33. 33.
    Arcasoy MO (2008) The non-haematopoietic biological effects of erythropoietin. Brit J Haematol 141:14–31CrossRefGoogle Scholar
  34. 34.
    Bolger AP, Bartlett FP, Penston HS et al (2006) Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48:1225–1227PubMedCrossRefGoogle Scholar
  35. 35.
    Toblli J, Lombrana A, Duarte P et al (2007) Intravenous iron reduces NT- pro-BNP in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50:1657–1665PubMedCrossRefGoogle Scholar
  36. 36.
    Usmanov RI, Zueva EB, Silverberg DS (2008) Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic renal insufficiency. J Nephrology 21:236–242Google Scholar
  37. 37.
    Okonko DO, Grzeslo A, Witkowski T et al (2008) Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. J Am Coll Cardiol 51:103–112PubMedCrossRefGoogle Scholar
  38. 38.
    Anker SD, Comin Colet J, Fillipatos G et al (2009) Ferric Carboxymaltose in patients with heart failure and iron deficiency. New Engl J Med 361:2436–2448PubMedCrossRefGoogle Scholar
  39. 39.
    Matsumoto M, Tsujino T, Masaaki L-K et al (2010) Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. Circulation J 74:301–306CrossRefGoogle Scholar
  40. 40.
    Dong F, Zhang X, Culver B et al (2005) Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrosome C release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Science 109:277–286CrossRefGoogle Scholar
  41. 41.
    Naito Y, Tsujino T, Matsumoto M et al (2009) Adaptive response of the heart to long term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 296:H585–H593PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of NephrologyTel Aviv Medical CenterTel AvivIsrael

Personalised recommendations